Trial Profile

A clinical study of IC 100 as a potential treatment for obesity and metabolic syndrome (obesity-associated metabolic comorbidities)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 16 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 May 2025 According to a ZyVersa Therapeutics media release, Results are anticipated in the first half of 2026.
12 May 2025 According to a ZyVersa Therapeutics media release, This trial will be supported by an IC 100 preclinical study in a diet-induced mouse model, with an interim data read-out expected in the second half of 2025.
07 May 2025 According to a ZyVersa Therapeutics media release, company expect to submit an Investigational New Drug (IND) application for IC 100 in H2-2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com